FRONTLINE PLC REPORTS RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 Frontline plc (the “Company”, “Frontline,” “we,” “us,” or “our”), today reported unaudited results for the six months ended June 30, 2025: HighlightsProfit of $77.5 million, or $0.35 per share for the second quarter of 2025. Adjusted profit of $80.4 million, or $0.36 per share for the second quarter of 2025. Declared a cash dividend of $0.36 per share for the second quarter of 2025. Reported revenues of $480.1 million for the second quarter of 2025. Achieved average daily spot time charter equivalent earnings (“TCEs”)1 for VLCCs, Suezmax tankers and LR2/Aframax tankers in the second quarter of $43,100, $38,900 and $29,300 per day, respectively. Entered into a senior secured term loan facility in April 2025 in an amount of up to $1,286.5 million to refinance...

Oslo (Norway), 29 August 2025 – PCI Biotech (OSE: PCIB), today announces its half-yearly 2025 interim report. Please find enclosed the interim report and presentation. Highlights review OperationsPCI Biotech decided on 18th August 2025 to discontinue further development of the PCL technology. The decision was primarily based on, as described in a press release the same day, insufficient progress towards the 2025 goal of demonstrating improved net yield at mini benchtop bioreactor scale. Achieving successful results at this scale was a critical risk-reducing milestone for further development. Following the progress reported in the preliminary 2024 Interim Report and the Annual Report 2024, additional initiatives were undertaken to demonstrate PCL’s capability to increase net AAV yield in an end-to-end process. However, these efforts did...

Dear shareholder, Dear Madam, Dear Sir,Ackermans & van Haaren publishes today its Half-Year 2025 Results  Strong results of core participations support the growth of Ackermans & van Haaren’s H1 2025 profit to 273 million euros (+36%)Record half-year results at DEME, Delen Private Bank, Bank Van Breda and SIPEF Significant improvement of results at Nextensa Outlook (strengthened): net profit for the full-year 2025 is expected to increase by at least 15% Positive net cash position of 431 million eurosPlease find annexed the full press release. Best regards Ackermans & van HaarenAttachmentAvH First-Half 2025 Results – Press Release (20250829)

CoinShares Announces Q2 2025 Results 29th August 2025 | SAINT HELIER, Jersey | CoinShares International Limited (“CoinShares” or “the Group”) (Nasdaq Stockholm: CS; US OTCQX: CNSRF), the leading European asset manager specialising in digital assets, has today published its results for the quarter ending 30th June 2025. Q2 2025 Financial HighlightsAsset Management fees of $30.0 million (Q2 2024: $28.3 million) Capital Markets gains/income of $11.3 million (Q2 2024: $14.6 million) Adjusted EBITDA of $26.3 million (Q2 2024: $25.5 million*) Treasury gain of $7.8 million (Q2 2024: $0.4 million loss) Net profit of $32.4 million (Q2 2024: $31.8 million) EPS (basic) for Q2 2025 of $0.49 (Q2 2024: $0.47) Total comprehensive income of $33.0 million (Q2 2024: $32.6 million)*Presented exclusive of FTX claim sale income and FlowBank impairment Jean-Marie...

RomReal hereby announces the results of the second quarter 2025 via the Report and an Investor presentation attached to this message. For further information, pls contact investors@romreal.comThis information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentsRomReal Q2 2025 PresentationRomReal Q2 2025 Report

Financial Results and Operational Update for the Full Year Ended June 30, 2025 NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2025. Mesoblast Chief Executive Dr. Silviu Itescu said, “This has been a banner year for the Company, with achievement of FDA approval for Ryoncil®, the first and only FDA approved mesenchymal stromal cell (MSC) product in the United States and a successful commercial launch of the product for treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients aged 2 months and older (“children”).” ”We are working tirelessly to transform Mesoblast into a fast-paced commercial biotechnology...

VANCOUVER, British Columbia, Aug. 28, 2025 (GLOBE NEWSWIRE) — Central 1 Credit Union (Central 1) today reported its 2025 second quarter financials, reflecting strong results in the treasury line of business and investments for growth of the payments line of business. “Our results are showing steady performance for 2025, reflecting the renewed focus on our core payments and treasury lines of business since transferring digital banking operations to Intellect Design in the first quarter of 2025,” said Sheila Vokey, President & CEO of Central 1. “In the first half of the year, we’ve made meaningful investment and progress to evolve our business and to strengthen our position as a trusted aggregated services provider for Canadian credit unions and other financial service organizations.” Second quarter 2025 compared with the second...

All dollar amounts reflected in Canadian dollars unless otherwise stated VANCOUVER, British Columbia, Aug. 28, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced its financial results for the three months ended June 30, 2025 (“Q2 2025”), and provided an update on recent corporate developments. Q2 2025 Financial HighlightsReported a net loss of $2,916,944. Research and development (R&D) expenses were $1,611,985, reflecting continued advancement of AI-powered drug candidates. General and administrative (G&A) expenses were $1,213,489 including investor & public relations and exchange-related fees. Operating expense cash burn (non-IFRS measure) was approximately...

Q2’25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M – $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2025. “Our strong commercial performance was driven by the continued adoption of our highly differentiated AI-enabled aprevo® technology platform and growing recognition of its ability to deliver more favorable patient outcomes than legacy devices,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “Building upon our momentum in personalized lumbar fusion surgery, in July we successfully completed the first personalized cervical spine surgery using our aprevo® technology...

VANCOUVER, British Columbia, Aug. 28, 2025 (GLOBE NEWSWIRE) — AIP Realty Trust (the “Trust” or “AIP Realty”) (TSXV:AIP.U) today announced its financial results for the three and six months ended June 30, 2025. All dollar amounts are stated in U.S. dollars. Q2 2025 HighlightsInvestment property revenue for the three ended June 30, 2025 was $150,403, compared to $152,591 in the same period in 2024, a decrease of $2,188, or 1%. The decline in investment property revenue was mainly due to a decline in parking revenue from a 2024 lease expiration that included a large parking agreement component and normal turnover that resulted in the vacancy of one unit starting in mid April 2025, partially offset by increased other revenue generated by tenant move-out charges. Investment property operating expense for the three months ended June...